The Latest Developments at Triskelion

LNP Analytics

Beyond Particle Size: Building a Complete Analytical Strategy for LNPs

Pharma's Almanac

Nonviral Delivery

Can Nonviral Delivery Change the Economics of Gene Therapy?

David Alvaro, Ph.D.

Pharma's Almanac

DDC Development

Building Better Combination Products by Engaging Device Development Earlier

Loganathan S.

OneSource Specialty Pharma

CCS and CMC

Packaging Returns to the Center of CMC Strategy

Pharma's Almanac

Partner Selection

How are organizations balancing cost with regulatory, supply chain, and reputational risk when selecting partners or sites?

Pharma's Almanac

Masked Antibody

Expanding the Oncology Therapeutic Window Through Masked Antibody Technology

Sean McCarthy, Ph.D; David Alvaro, Ph.D.

CytomX Therapeutics

Self-Injection

The Quiet Revolution in How We Take Our Medicine

Ravi Kumar

OneSource Specialty Pharma

Combination Products

Collaboration is Key to Successful Injectable Drug–Device Combination Product Development

Cynthia A. Challener, Ph.D.

Pharma's Almanac

High-Concentration

High-Concentration Biologics Are Redefining Subcutaneous Delivery

Pharma's Almanac

Drug Delivery

Intracellular Delivery: Reaching Targets Beyond the Cell Surface

David Alvaro, Ph.D.

Pharma's Almanac

Next-Gen Delivery

Beyond Lipid Nanoparticles: The Search for Next-Generation Delivery Platforms

Pharma's Almanac